US Patent Issued to Istituto Oncologico Veneto IOV-IRCCS on May 13 for "Marker for identifying patients with gliobastoma who respond positively to the drug regorafenib" (Italian Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,298,306, issued on May 13, was assigned to Istituto Oncologico Veneto IOV-IRCCS (Padua, Italy).

"Marker for identifying patients with gliobastoma who respond positively to the drug regorafenib" was invented by Stefano Indraccolo (Padua, Italy), Gian Luca De Salvo (Padua, Italy) and Giuseppe Lombardi (Padua, Italy).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a marker for allowing the identification of patients with glioblastoma who respond positively to the drug Regorafenib."

The patent was filed on March 12, 2019, under Application No. 16/980,122.

*For further information, including images, charts and tables, please ...